Romness Paul A. 4/A

What Happened

• Paul A. Romness, President, CEO and director of OS Therapies (OSTX), received a grant of options covering 1,000,000 shares on October 21, 2025. The Form 4 reports the award as a derivative acquisition (Table II) with $0.00 shown for acquisition price; the filing does not disclose an exercise price or dollar value.
• This was an option award (code A), not an open-market purchase or immediate sale — it gives the right to buy shares later subject to exercise and vesting, rather than immediate ownership.

Key Details

• Transaction date: October 21, 2025 (reported on an amended Form 4 filed February 13, 2026).
• Award: options to purchase 1,000,000 shares; Table II shows $0.00 acquisition amount for reporting purposes.
• Vesting: footnote F1 states the options vest in full on the one-year anniversary of the grant, provided Romness remains employed by the company on that date.
• Filing status: This is an amended Form 4. The filer notes an earlier Form 4 filed December 19, 2025 incorrectly reported the number of underlying shares; this amendment corrects Table II.
• Shares owned after transaction: Not specified in the amended filing.

Context

• Option grants create potential future ownership if the options are exercised after vesting; they are commonly used as compensation and do not represent an immediate market buy or sell. Because this filing corrects a prior report and was amended, investors should rely on the amended numbers for the accurate count of shares underlying the award.